PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

#2

In re application of

Docket No: Q85611

Masakazu SATO, et al.

National Stage Application of PCT/JP03/10159
-filed August 8, 2003

Confirmation No.: Not Yet Assigned

Group Art Unit: Not Yet Assigned

Filed: January 21, 2005

Examiner: Not Yet Assigned

For: METHOD FOR SELECTIVE

PREPARATION OF ARYL 5-THIO-β-D-

ALDOHEXOPYRANOSIDES

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.97 and 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003.

National Stage Application of PCT/JP03/10159
-filed August 8, 2003

Q85611

WO 03/000712 is cited in the first full paragraph of page 2 of the subject application. EP 1 405 859 is a corresponding application and is submitted as a concise statement of relevance of WO 03/000712.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after filing a request for continued examination (RCE) under §1.114, and therefore, no Statement under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

The submission of the listed documents is not intended as an admission that any such document constitutes prior art against the claims of the present application. Applicant does not waive any right to take any action that would be appropriate to antedate or otherwise remove any listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any overpayments to said Deposit Account.

Respectfully submitted,

Registration No. 30,951

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373
CUSTOMER NUMBER

Date: January 21, 2005

DT12 Rec'd PCT/PTO 2 1 JAN 2005

MODIFIED DTO/CD/09 A & D (06 03)

			MODII ILD I 10/3B/06 A & B (00-03)
		-mp	lete if Kholh / 521809
Substitute for Form 1449 A & B/PTO			National Stage Application of PCT/JP03/10159
INFORMATION DISCLO	SURE	Application Number	-filed August 8, 2003
STATEMENT BY APPLIC	CANT	Confirmation Number	Not Yet Assigned
		Filing Date	January 21, 2005
(use as many sheets as necesso	ry)	First Named Inventor	Masakazu SATO
()	,	Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
Sheet 1 of	1	Attorney Docket Number	Q85611

			U.S.	PATENT DOCUMI	ENTS
		Document Nun	nber		
Examiner Initials*	Cite No. ¹		Code ²	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
		US 2004/0063646	Al	04-01-2004	Fujikura, et al.

	FOREIGN PATENT DOCUMENTS									
Examiner Cite	Cite	For	reign Patent Docun	nent	Publication Date	Name of Patentee or	m 6			
Initials*		Applicant of Cited Document	Translation ⁶							
		EP	1 405 859	Al	04-07-2004	Kissei Pharmaceutical Co., Ltd.				
		WO	03/000712	Al	01-03-2003	Kissei Pharmaceutical Co., Ltd.				
				1						
)										

			A444 HT							
				<u> </u>						
				1						

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶		

Examiner Signature	Date Considered	<u> </u>

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.

DT12 Rec'd PCT/PTO 2 1 JAN 2005

MODIFIED PTO/SB/08 A & B (06-03)

Substitute	for	Form	1440	۸	R,	R/PTO
Substitute	101	rorm	1447	4	œ	DIFIO

Sheet

REFERENCES CITED IN THE INTERNATIONAL SEARCH REPORT

(use as many sheets as necessary)

of

L. I.	plete if And In 521809
	National Stage Application of PCT/JP03/10159
Application Number	-filed August 8, 2003
Confirmation Number	Not Yet Assigned
Filing Date	January 21, 2005
First Named Inventor	Masakazu SATO
Art Unit	Not Yet Assigned
Examiner Name	Not Yet Assigned
Attorney Docket Number	Q85611

			U.S. I	PATENT DOCUME	ENTS
F	Cite	Document	Number	Publication Date	
Examiner Initials*	No.1	Number	Kind Code ² (if known)	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
					

			F	OREIGN PA	TENT DOCUME	ENTS	
Examiner Cite	Foreign Patent Document			Publication Date	Name of Patentee or	Translation ⁶	
Initials*	No.1	Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY	Applicant of Cited Document	Translation
	··· <u>-</u>	WO	01/16147	Al	03-08-2001	Kissei Pharmaceutical Co., Ltd.	
		EP	1213296	Al	06-12-2002	Kissei Pharmaceutical Co., Ltd.	
		WO	01/68660	Al	09-20-2001	Kissei Pharmaceutical Co., Ltd.	
		EP	1270584	Al	01-02-2003	Kissei Pharmaceutical Co., Ltd.	
		WO	01/74834	Al	10-11-2001	Bristol Myers Squibb Co	
		WO	01/74835	Al	10-11-2001	Bristol Myers Squibb Co	
		WO	02/36602	Al	05-10-2002	Ajinomoto Co., Inc.	
		EP	1338603	Al	08-27-2003	Ajinomoto Co., Inc.	
		WO	02/053573	Al	07-11-2002	Kissei Pharmaceutical Co., Ltd.	
		JP	10-237089	A	09-08-1998	Tanabe Seiyaku Co., Ltd.	
		EP	850948	Al	07-01-1998	Tanabe Seiyaku Co., Ltd.	
							·

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.	Translation ⁶
		BOZO, et al. "Synthesis of 4-cyanophenyl and 4-nitrophenyl 1,5-dithio-L- and -D-arabinopyranosides possessing antithrombotic activity"., Carbohydrate Research, 1998, 311, pages 191-202	
		K.D. RANDELL, et al. "Synthesis and glycosides inhibitory activity of 5-thioglucopyranosylamines. Molecular modeling of complexes with glucoamilase., Carbohydrate Research, 1999, 321, pages 143-156	
	.,	H. YUASA, et al. "Relative Nucleophilicity of the Two Sulfur Atoms in 1,5-Dithioglucopyranoside., Angew. Chem. Int. Ed. Engl., 1997, 36(8), pages 868-870	

	· · · · · · · · · · · · · · · · · · ·		
Examiner Signature		 Date Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.